1
|
Tezuka Y, Omata K, Ono Y, Kambara K, Kamada H, Oguro S, Yamazaki Y, Gomez-Sanchez CE, Ito A, Sasano H, Takase K, Tanaka T, Katagiri H, Satoh F. Investigating the cut-off values of captopril challenge test for primary aldosteronism using the novel chemiluminescent enzyme immunoassay method: a retrospective cohort study. Hypertens Res 2024; 47:1362-1371. [PMID: 38454147 DOI: 10.1038/s41440-024-01594-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 12/26/2023] [Accepted: 01/13/2024] [Indexed: 03/09/2024]
Abstract
The measurement evolution enabled more accurate evaluation of aldosterone production in hypertensive patients. However, the cut-off values for novel assays have been not sufficiently validated. The present study was undertaken to validate the novel chemiluminescent enzyme immunoassay for aldosterone in conjunction with other methods. Moreover, we also aimed to establish a new cut-off value for primary aldosteronism in the captopril challenge test using the novel assay. First, we collected 390 plasma samples, in which aldosterone levels measured using liquid chromatography-mass spectrometry ranged between 0.18 and 1346 ng/dL. The novel chemiluminescent enzyme immunoassay showed identical correlation of plasma aldosterone with liquid chromatography-mass spectrometry, in contrast to conventional radioimmunoassay. Further, we enrolled 299 and 39 patients with primary aldosteronism and essential hypertension, respectively. Plasma aldosterone concentrations measured using the novel assay were lower than those measured by radioimmunoassay, which resulted in decreased aldosterone-to-renin ratios. Subsequently, positive results of the captopril challenge test based on radioimmunoassay turned into "negative" based on the novel assay in 45% patients with primary aldosteronism, using the conventional cut-off value (aldosterone-to-renin activity ratio > 20 ng/dL per ng/mL/h). Receiver operating characteristic curve analysis demonstrated that aldosterone-to-renin activity ratios > 8.2 ng/dL per ng/mL/h in the novel assay was compatible with the conventional diagnosis (sensitivity, 0.874; specificity, 0.980). Our study indicates the great measurement accuracy of the novel chemiluminescent enzyme immunoassay for aldosterone, and the importance of measurement-adjusted cut-offs in the diagnosis of primary aldosteronism.
Collapse
Affiliation(s)
- Yuta Tezuka
- Department of Diabetes, Metabolism, and Endocrinology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan
- Division of Nephrology, Rheumatology, and Endocrinology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
| | - Kei Omata
- Department of Diabetes, Metabolism, and Endocrinology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan
- Division of Nephrology, Rheumatology, and Endocrinology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
| | - Yoshikiyo Ono
- Department of Diabetes, Metabolism, and Endocrinology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan
- Division of Nephrology, Rheumatology, and Endocrinology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
| | - Kengo Kambara
- Medical Systems Research & Development Center, Medical Systems Business Division, FUJIFILM Corporation, 6-1, Takata-cho, Amagasaki-shi, Hyogo, 661-0963, Japan
| | - Hiroki Kamada
- Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
| | - Sota Oguro
- Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
| | - Yuto Yamazaki
- Department of Pathology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
| | - Celso E Gomez-Sanchez
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
| | - Akihiro Ito
- Department of Urology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan
| | - Hironobu Sasano
- Department of Pathology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
| | - Kei Takase
- Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
| | - Tetsuhiro Tanaka
- Division of Nephrology, Rheumatology, and Endocrinology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
| | - Hideki Katagiri
- Department of Diabetes, Metabolism, and Endocrinology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan
| | - Fumitoshi Satoh
- Division of Nephrology, Rheumatology, and Endocrinology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
| |
Collapse
|
2
|
Nishikawa T, Nakai K, Tsurutani Y, Matsuzawa Y, Saito J, Omura M. Where and how are we going? Simplifying the definitive diagnosis of primary aldosteronism. Hypertens Res 2024:10.1038/s41440-024-01666-y. [PMID: 38584160 DOI: 10.1038/s41440-024-01666-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Revised: 03/08/2024] [Accepted: 03/13/2024] [Indexed: 04/09/2024]
Affiliation(s)
- Tetsuo Nishikawa
- Endocrinology & Diabetes Center, Yokohama Rosai Hospital, Yokohama, Japan.
- Nishikawa Clinic, Yokohama, Japan.
| | - Kazuki Nakai
- Endocrinology & Diabetes Center, Yokohama Rosai Hospital, Yokohama, Japan
| | - Yuya Tsurutani
- Endocrinology & Diabetes Center, Yokohama Rosai Hospital, Yokohama, Japan
| | - Yoko Matsuzawa
- Endocrinology & Diabetes Center, Yokohama Rosai Hospital, Yokohama, Japan
- Matsuzawa Clinic, Yokohama, Japan
| | - Jun Saito
- Endocrinology & Diabetes Center, Yokohama Rosai Hospital, Yokohama, Japan
| | - Masao Omura
- Endocrinology & Diabetes Center, Yokohama Rosai Hospital, Yokohama, Japan
- Minato Mirai Medical Square, Yokohama, Japan
| |
Collapse
|
3
|
Nakai K, Tsurutani Y, Irie K, Teruyama K, Suematsu S, Matsui S, Makita K, Saito J, Omura M, Nishikawa T. Adrenal venous sampling criteria for chemiluminescent enzyme immunoassay as a preferable alternative to radioimmunoassay in primary aldosteronism. Endocr J 2024:EJ23-0695. [PMID: 38417879 DOI: 10.1507/endocrj.ej23-0695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/01/2024] Open
Abstract
Plasma aldosterone concentration (PAC) was routinely measured using radioimmunoassay (RIA); however, the RIA kit was discontinued in March 2021 in Japan. This study examined PAC conversion in adrenal venous sampling (AVS) and AVS criteria when measured using chemiluminescent enzyme immunoassay (CLEIA). PAC of 415 adrenal venous blood samples from AVS (including segmental AVS) of 63 patients with primary aldosteronism was measured using RIA (Spac-S aldosterone kit; Fujirebio Inc.) and CLEIA (Lumipulse Presto Aldosterone; Fujirebio Inc.). PAC of 70 AVS samples was also measured using liquid chromatography-mass spectrometry (LC-MS/MS, ASKA Pharma Medical Co., Ltd.). PAC conversion formulas were determined for each AVS sample assay. PAC measured using CLEIA was significantly correlated with that measured using RIA (correlation coefficient = 0.971). The PAC conversion formula was PAC (CLEIA) = PAC (RIA) × 0.772 - 1,199 pg/mL. The PAC of 14,000 pg/mL in RIA was equivalent to 9,613 pg/mL in CLEIA. PAC measured using CLEIA was also correlated with that measured using LC-MS/MS, and the PAC conversion formula was PAC (CLEIA, pg/mL) = 0.97 × PAC (LC-MS/MS, pg/mL) + 211. The inter-assay coefficient of variability (CV) was 1.1-1.3% and intra-assay CV was 1.0-1.7%, measured using CLEIA. The PAC conversion formula for AVS samples was obtained using CLEIA and RIA, and the conversion formula was different from that for peripheral blood. PAC values measured by CLEIA showed preferable accuracy and high concordance with those measured by LC-MS/MS, even in AVS samples. The study outcomes are useful for interpreting AVS results using non-RIA measurement methods.
Collapse
Affiliation(s)
- Kazuki Nakai
- Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Kanagawa 222-0036, Japan
| | - Yuya Tsurutani
- Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Kanagawa 222-0036, Japan
| | - Koki Irie
- Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Kanagawa 222-0036, Japan
- Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - Kyoko Teruyama
- Product Planning Department, Fujirebio Inc., Tokyo 107-0052, Japan
| | - Sachiko Suematsu
- Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Kanagawa 222-0036, Japan
| | - Seishi Matsui
- Department of Radiology, Yokohama Rosai Hospital, Kanagawa 222-0036, Japan
| | - Kohzoh Makita
- Department of Radiology, Nerima Hikarigaoka Hospital, Tokyo 179-0072, Japan
| | - Jun Saito
- Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Kanagawa 222-0036, Japan
| | - Masao Omura
- Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Kanagawa 222-0036, Japan
- Minato Mirai Medical Square, Kanagawa 220-0012, Japan
| | - Tetsuo Nishikawa
- Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Kanagawa 222-0036, Japan
- Nishikawa Clinic, Kanagawa 222-0033, Japan
| |
Collapse
|
4
|
Deng W, Wang D, Dai P, Hong Y, Xiong J, Duan L, Lu R, Wan J, Du H, Hammock BD, Yang W. Development of a sensitive direct competitive chemiluminescent enzyme immunoassay for gentamicin based on the construction of a specific single-chain variable fragment-alkaline phosphatase fusion protein. Microchem J 2024; 197:109706. [PMID: 38283367 PMCID: PMC10810264 DOI: 10.1016/j.microc.2023.109706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2024]
Abstract
A sensitive chemiluminescent enzyme immunoassay (CLEIA) was established for the determination of gentamicin (GEN) residue levels in animal tissue. This assay is based on a fusion protein of single-chain variable fragment (scFv) and alkaline phosphatase (AP). Initially, VL and VH derived from anti-gentamicin monoclonal antibody were linked by a short peptide to construct a scFv. Subsequently, the constructed scFv sequence was accessed into the pLIP6/GN vector, and a soluble scFv-AP fusion protein was generated. The scFv-AP fusion protein was used to develop a direct competitive CLEIA (dcCLEIA) for the determination of gentamicin. In the dcCLEIA, the half inhibitory concentration (IC50) and limit of detection (LOD) were 1.073 ng/mL and 0.380 ng/mL, respectively. The average recoveries of gentamicin spiked in animal tissue samples ranged from 78% to 96%. These results showed a strong correlation with ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). The above results suggest that the anti-GEN scFv-AP fusion protein is suitable for detecting gentamicin residues in edible animal tissues.
Collapse
Affiliation(s)
- Weijie Deng
- Key Laboratory of Agricultural Products Processing and Quality Control of Nanchang City/College of Food Science and Engineering, Jiangxi Agricultural University, Nanchang 330045, China
| | - Dan Wang
- Key Laboratory of Agricultural Products Processing and Quality Control of Nanchang City/College of Food Science and Engineering, Jiangxi Agricultural University, Nanchang 330045, China
| | - Peng Dai
- Key Laboratory of Agricultural Products Processing and Quality Control of Nanchang City/College of Food Science and Engineering, Jiangxi Agricultural University, Nanchang 330045, China
| | - Yanping Hong
- Key Laboratory of Agricultural Products Processing and Quality Control of Nanchang City/College of Food Science and Engineering, Jiangxi Agricultural University, Nanchang 330045, China
| | - Jianhua Xiong
- Key Laboratory of Agricultural Products Processing and Quality Control of Nanchang City/College of Food Science and Engineering, Jiangxi Agricultural University, Nanchang 330045, China
| | - Luying Duan
- Key Laboratory of Agricultural Products Processing and Quality Control of Nanchang City/College of Food Science and Engineering, Jiangxi Agricultural University, Nanchang 330045, China
| | - Ruimin Lu
- Key Laboratory of Agricultural Products Processing and Quality Control of Nanchang City/College of Food Science and Engineering, Jiangxi Agricultural University, Nanchang 330045, China
| | - Jianchun Wan
- Technology Center of Nanchang Customs District, Nanchang 330038, China
| | - Huaying Du
- Key Laboratory of Agricultural Products Processing and Quality Control of Nanchang City/College of Food Science and Engineering, Jiangxi Agricultural University, Nanchang 330045, China
| | - Bruce D. Hammock
- Department of Entomology and Nematology and UCD Comprehensive Cancer Center, University of California, Davis, CA 95616, United States
| | - Wuying Yang
- Key Laboratory of Agricultural Products Processing and Quality Control of Nanchang City/College of Food Science and Engineering, Jiangxi Agricultural University, Nanchang 330045, China
- Department of Entomology and Nematology and UCD Comprehensive Cancer Center, University of California, Davis, CA 95616, United States
| |
Collapse
|
5
|
Abstract
Hyperkalemia is developed in a part of patients with aldosterone-producing adenoma (APA) after adrenalectomy, suspected to be due to the insufficiency of aldosterone secretion. The purpose of this study is to determine the frequency and characteristics of prolonged postoperative hypoaldosteronism (PPHA) using chemiluminescent enzyme immunoassay (CLEIA). We studied 58 patients with APA with long time after adrenalectomy and whose PAC was measured using a CLEIA kit. The PAC value measured using CLEIA was significantly lower than that of using RIA between two consecutive visits before and after the shift of measuring method of PAC (median [interquantile range], 123.0 [99.8-164.0] vs. 39.5 [15.8-64.2] pg/mL, p < 0.01). PAC was below the minimum limit of quantification (4.0 pg/mL) of the CLEIA kit at least once in nine patients (15.5%) who had PPHA. The PPHA group were older (mean ± standard deviation, 61.3 ± 8.5 vs. 50.5 ± 10.1 years, p < 0.01) and had lower eGFR (60.3 ± 14.0 vs. 82.3 ± 22.8 mL/min/1.73 m2, p < 0.01) than the non-PPHA group. The frequency of postoperative hyperkalemia (maximum serum potassium >5.5 mEq/L) was higher in the PPHA group than in the non-PPHA group (55.6% vs. 8.2%, p < 0.01). In conclusion, a few patients with APA long time after adrenalectomy had unmeasurable PAC using CLEIA. PPHA is likely to develop in patients with APA after adrenalectomy who are older and have impaired renal function. Additionally, PPHA is related to the occurrence of postoperative hyperkalemia.
Collapse
Affiliation(s)
- Norio Wada
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Shuhei Baba
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Hajime Sugawara
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Arina Miyoshi
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Shinji Obara
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| |
Collapse
|
6
|
Aoki K, Nagasawa T, Ishii Y, Yagi S, Okuma S, Kashiwagi K, Maeda T, Miyazaki T, Yoshizawa S, Tateda K. Clinical validation of quantitative SARS-CoV-2 antigen assays to estimate SARS-CoV-2 viral loads in nasopharyngeal swabs. J Infect Chemother 2020; 27:613-616. [PMID: 33423918 PMCID: PMC7713570 DOI: 10.1016/j.jiac.2020.11.021] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Revised: 11/04/2020] [Accepted: 11/22/2020] [Indexed: 12/23/2022]
Abstract
BACKGROUND Expansion of the testing capacity for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important issue to mitigate the pandemic of coronavirus disease-2019 (COVID-19) caused by this virus. Recently, a sensitive quantitative antigen test (SQT), Lumipulse® SARS-CoV-2 Ag, was developed. It is a fully automated chemiluminescent enzyme immunoassay system for SARS-CoV-2. METHODS In this study, the analytical performance of SQT was examined using clinical specimens from nasopharyngeal swabs using reverse transcription polymerase chain reaction (RT-PCR) as a control. RESULTS Receiver operating characteristic analysis of 24 SARS-CoV-2-positive and 524 -negative patients showed an area under the curve of 0.957 ± 0.063. Using a cut-off value of 1.34 pg/ml, the sensitivity was 91.7%, the specificity was 98.5%, and the overall rate of agreement was 98.2%. In the distribution of negative cases, the 99.5 percentile value was 1.03 pg/ml. There was a high correlation between the viral load calculated using the cycle threshold value of RT-PCR and the concentration of antigen. The tendency for the antigen concentration to decrease with time after disease onset correlated with that of the viral load. CONCLUSIONS Presented results indicate that SQT is highly concordant with RT-PCR and should be useful for the diagnosis of COVID-19 in any clinical setting. Therefore, this fully automated kit will contribute to the expansion of the testing capability for SARS-CoV-2.
Collapse
Affiliation(s)
- Kotaro Aoki
- Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan
| | - Tatsuya Nagasawa
- Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan
| | - Yoshikazu Ishii
- Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan.
| | - Shintaro Yagi
- Fujirebio Inc., 51 Komiya-machi, Hachioji, 192-0031, Tokyo, Japan
| | - Sadatsugu Okuma
- Fujirebio Inc., 51 Komiya-machi, Hachioji, 192-0031, Tokyo, Japan
| | - Katsuhito Kashiwagi
- General Medicine and Emergency Center (Internal Medicine), Toho University Omori Medical Center, 6-11-1 Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan
| | - Tadashi Maeda
- General Medicine and Emergency Center (Internal Medicine), Toho University Omori Medical Center, 6-11-1 Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan
| | - Taito Miyazaki
- General Medicine and Emergency Center (Internal Medicine), Toho University Omori Medical Center, 6-11-1 Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan
| | - Sadako Yoshizawa
- Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan
| | - Kazuhiro Tateda
- Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan
| |
Collapse
|
7
|
Lin J, Yu J, Wang H, Xu Y, Li F, Chen X, Liang Y, Tang J, Wu L, Zhou Z, Chen C, Liu M, Chun X, Nian R, Song H. Development of a highly thermostable immunoassay based on a nanobody-alkaline phosphatase fusion protein for carcinoembryonic antigen detection. Anal Bioanal Chem 2020; 412:1723-1728. [PMID: 32030492 DOI: 10.1007/s00216-020-02456-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Revised: 01/14/2020] [Accepted: 01/24/2020] [Indexed: 10/25/2022]
Abstract
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM-5) assays are employed in routine clinical settings to diagnose tumor. We selected two nanobodies with high-affinity to CEACAM-5, termed Nb11C12 and Nb2D5, using phage-display technology. The Nb2D5 fused with calf intestinal alkaline phosphatase (CAP), human placental alkaline phosphatase (HAP), or Pyrococcus abyssi alkaline phosphatase (PAP) were expressed in human embryonic kidney (HEK293) cells. The enzymatic activity of Nb2D5-HAP fusion protein was the best and remained stable at 60 °C for 7 days. The affinity of Nb2D5-HAP fusion protein to CEACAM-5 reached 42 pM. A chemiluminescent enzyme immunoassay (CLEIA) based on Nb2D5-HAP fusion protein was established for quantitative CEACAM-5 assay in clinical settings. The CLEIA exhibited a wide linear range of 0.31-640 ng/mL toward CEACAM-5, with a limit of detection (LOD) of 0.85 ng/mL. No cross-reactivity occurred with CEACAM-1, CEACAM-3, CEACAM-6, or CEACAM-8, and no interference was observed with rheumatoid factors. The CLEIA based on Nb2D5-HAP fusion protein was stable for 8 weeks at 37 °C and 50% relative humidity. The CLEIA developed from Nb2D5-HAP fusion protein had much better stability and linearity with similar reproducibility compared with the enzyme-linked immunosorbent assay developed from conventional monoclonal antibodies, which have been widely used in clinics over the past several decades. Graphical abstract.
Collapse
Affiliation(s)
- Jingtao Lin
- Dalang Hospital of Dongguan, No. 85 Jinlangzhong Road, Dalang, Dongguan, 523770, Guangdong, China
| | - Jianli Yu
- CAS Key Laboratory of Biobased Materials, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, No. 189 Songling Road, Qingdao, 266101, Shandong, China.,University of Chinese Academy of Sciences, No.19 (A) Yuquan Road, Beijing, 100049, China
| | - Huan Wang
- Shenzhen Innova Nanobodi Co., Ltd., No. 7018 Caitian Road, Shenzhen, 518000, Guangdong, China
| | - Yanru Xu
- Dalang Hospital of Dongguan, No. 85 Jinlangzhong Road, Dalang, Dongguan, 523770, Guangdong, China
| | - Fei Li
- Shenzhen Innova Nanobodi Co., Ltd., No. 7018 Caitian Road, Shenzhen, 518000, Guangdong, China
| | - Xiaoheng Chen
- Shenzhen Innova Nanobodi Co., Ltd., No. 7018 Caitian Road, Shenzhen, 518000, Guangdong, China
| | - Yunlong Liang
- CAS Key Laboratory of Biobased Materials, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, No. 189 Songling Road, Qingdao, 266101, Shandong, China
| | - Jinsong Tang
- Dalang Hospital of Dongguan, No. 85 Jinlangzhong Road, Dalang, Dongguan, 523770, Guangdong, China
| | - Lili Wu
- Dalang Hospital of Dongguan, No. 85 Jinlangzhong Road, Dalang, Dongguan, 523770, Guangdong, China
| | - Zhengwei Zhou
- Dalang Hospital of Dongguan, No. 85 Jinlangzhong Road, Dalang, Dongguan, 523770, Guangdong, China
| | - Cailing Chen
- Dalang Hospital of Dongguan, No. 85 Jinlangzhong Road, Dalang, Dongguan, 523770, Guangdong, China
| | - Minjuan Liu
- Dalang Hospital of Dongguan, No. 85 Jinlangzhong Road, Dalang, Dongguan, 523770, Guangdong, China
| | - Xuan Chun
- Dalang Hospital of Dongguan, No. 85 Jinlangzhong Road, Dalang, Dongguan, 523770, Guangdong, China
| | - Rui Nian
- CAS Key Laboratory of Biobased Materials, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, No. 189 Songling Road, Qingdao, 266101, Shandong, China.
| | - Haipeng Song
- Shenzhen Innova Nanobodi Co., Ltd., No. 7018 Caitian Road, Shenzhen, 518000, Guangdong, China.
| |
Collapse
|
8
|
Obara T, Toyomaki K, Uegaki Y, Kikuchi Y, Arai J, Kuroda K, Suwabe A. Prozone-like phenomenon found in chemiluminescent enzyme immunoassay using magnetic particles for measurement of serum anti-single stranded DNA antibody titers: Definition and management. Clin Chim Acta 2018; 485:88-94. [PMID: 29928865 DOI: 10.1016/j.cca.2018.06.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Revised: 06/15/2018] [Accepted: 06/18/2018] [Indexed: 11/19/2022]
Abstract
BACKGROUND Serum anti-single stranded DNA antibody (anti-ssDNAab) is used as a marker for systemic lupus erythematosus. We found a 'prozone-like phenomenon,' which was different from an original prozone phenomenon, in chemiluminescent enzyme immunoassay using magnetic particles for the measurement of serum anti-ssDNAab titers. We investigated mechanisms of the prozone-like phenomenon and countermeasures to prevent it from being overlooked. METHODS This study examined 679 samples from patients tested for anti-ssDNAab titer at our hospital. In addition, the BF photometry OD value 2 (OD2), an index of optical density, was monitored simultaneously. RESULTS The undiluted samples with a prozone-like phenomenon showed extremely lower OD2. Those samples were able to be distinguished from other samples by setting OD2 criteria based on the 95% prediction interval. Significant differences (p < 0.05) were found in the titer ratios (ten-fold diluted against undiluted) between groups with >1.5 and other groups with <1.5 for the ratios of OD2. CONCLUSIONS We proposed two valuable methods to find a prozone-like phenomenon: one by setting OD2 criteria based on the 95% prediction interval and the other by analyzing the ratios both in titers and OD2 between undiluted and 10-fold diluted samples.
Collapse
Affiliation(s)
- Takehiro Obara
- Division of Central Clinical Laboratory, Iwate Medical University Hospital, Morioka, Japan.
| | - Kazushi Toyomaki
- Division of Central Clinical Laboratory, Iwate Medical University Hospital, Morioka, Japan
| | - Yurino Uegaki
- Division of Central Clinical Laboratory, Iwate Medical University Hospital, Morioka, Japan
| | - Yoshie Kikuchi
- Division of Central Clinical Laboratory, Iwate Medical University Hospital, Morioka, Japan
| | - Jiro Arai
- Medical & Biological Laboratories Co., Ltd., Nagoya, Japan
| | - Keiko Kuroda
- Medical & Biological Laboratories Co., Ltd., Nagoya, Japan
| | - Akira Suwabe
- Department of Laboratory Medicine, Iwate Medical University School of Medicine, Morioka, Japan
| |
Collapse
|
9
|
Toishi Y, Tsunoda N, Nagata SI, Kirisawa R, Nagaoka K, Watanabe G, Yanagawa Y, Katagiri S, Taya K. Evaluation of the chemiluminescent enzyme immunoassay system for the measurement of testosterone in the serum and whole blood of stallions. J Reprod Dev 2017; 64:41-47. [PMID: 29129877 PMCID: PMC5830357 DOI: 10.1262/jrd.2017-099] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Testosterone (T) concentration is a useful indicator of reproductive function in male animals. However, T concentration is not usually measured in veterinary clinics, partly due to the unavailability of reliable and
rapid assays for animal samples. In this study, a rapid chemiluminescent enzyme immunoassay system (CLEIA system) that was developed for the measurement of T concentration in humans use was validated for stallion blood
samples. First, serum T concentrations were measured using the CLEIA system and compared with those measured by a fluoroimmunoassay that has been validated for use in stallions. The serum T concentrations measured by the
two methods were highly correlated (r = 0.9865, n = 56). Second, to validate the use of whole blood as assay samples, T concentrations in whole blood and in the serum were measured by the CLEIA system. T concentrations
in both samples were highly correlated (r = 0.9665, n = 64). Finally, to evaluate the practical value of the CLEIA system in clinical settings, T concentrations were measured in three stallions with reproductive
abnormalities after the administration of human chorionic gonadotropin (hCG). Two stallions with small or absent testes in the scrotum showed an increase in T production in response to hCG administration and one stallion
with seminoma did not. In conclusion, the CLEIA system was found to be a rapid and reliable tool for measuring T concentrations in stallions and may improve reproductive management in clinical settings and in breeding
studs.
Collapse
Affiliation(s)
- Yuko Toishi
- Shadai Stallion Station, Hokkaido 059-1432, Japan.,Laboratory of Veterinary Virology, Department of Pathobiology, School of Veterinary Medicine, Rakuno Gakuen University, Hokkaido 069-8501, Japan
| | | | - Shun-Ichi Nagata
- Genetic Analysis Department, Laboratory of Racing Chemistry, Tochigi 320-0851, Japan
| | - Rikio Kirisawa
- Laboratory of Veterinary Virology, Department of Pathobiology, School of Veterinary Medicine, Rakuno Gakuen University, Hokkaido 069-8501, Japan
| | - Kentaro Nagaoka
- Laboratory of Veterinary Physiology, Cooperative Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Tokyo 183-8509, Japan.,United Graduated School of Veterinarian Science, Gifu University, Gifu 501-1193, Japan
| | - Gen Watanabe
- Laboratory of Veterinary Physiology, Cooperative Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Tokyo 183-8509, Japan.,United Graduated School of Veterinarian Science, Gifu University, Gifu 501-1193, Japan
| | - Yojiro Yanagawa
- Laboratory of Theriogenology, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Hokkaido 060-0808, Japan
| | - Seiji Katagiri
- Laboratory of Theriogenology, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Hokkaido 060-0808, Japan
| | - Kazuyoshi Taya
- Shadai Stallion Station, Hokkaido 059-1432, Japan.,Laboratory of Veterinary Physiology, Cooperative Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Tokyo 183-8509, Japan
| |
Collapse
|
10
|
Çetiner S, Çetin Duran A, Kibar F, Yaman A. Performance comparison of new generation HCV core antigen test versus HCV RNA test in management of hepatitis C virus infection. Transfus Apher Sci 2017; 56:362-366. [PMID: 28342642 DOI: 10.1016/j.transci.2017.02.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2016] [Revised: 02/03/2017] [Accepted: 02/22/2017] [Indexed: 12/28/2022]
Abstract
The study has evaluated the performance of HCV core antigen (Cag) test by comparing HCV RNA PCR assay which is considered the gold standard for management of HCV infection. Totally, 132 samples sent for HCV RNA (real-time PCR) test were included in the study. Anti-HCV antibody test and HCV Cag test were performed by chemiluminescent enzyme immunoassay (CMEI). Anti-HCV test was positive in all samples. HCV RNA was detected in 112/132 (84.8%) samples, and HCV Cag in 105/132 (79.5%). The most common HCV genotype was genotype 1 (86%). Considering the HCV RNA test as gold standard; the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of Cag test were found to be 93.75%, 100%, 100%, 74.07% and 94.69%, respectively, and paired test results were detected as highly concordant. A high level of correlation was seen between HCV RNA and Cag tests, however, the concordance between the two tests appeared to be disrupted at viral loads lower than 103IU/mL. On the contrary, the correlation reached significance for the values higher than 103IU/mL. Viral loads were in the 17-2500IU/mL range for the negative results for Cag test. Pearson's correlation coefficient revealed a considerably high correlation. The concordance between HCV RNA and Cag tests was disrupted under a viral load lower than 103IU/mL. Therefore, it would be appropriate to consider cost effectiveness, advantages and limitations of the HCV RNA and Cag tests during the decision on which method to use for patient management.
Collapse
Affiliation(s)
- Salih Çetiner
- Division of Basic Immunology, Balcali Hospital, Central Laboratory, Cukurova University, Adana, Turkey.
| | - Alev Çetin Duran
- Department of Medical Microbiology, Faculty of Medicine, Cukurova University, Adana, Turkey.
| | - Filiz Kibar
- Department of Medical Microbiology, Faculty of Medicine, Cukurova University, Adana, Turkey.
| | - Akgün Yaman
- Department of Medical Microbiology, Faculty of Medicine, Cukurova University, Adana, Turkey.
| |
Collapse
|
11
|
Fujio Y, Kojima K, Hashiguchi M, Wakui M, Murata M, Amagai M, Yamagami J. Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid. J Dermatol Sci 2017; 85:208-215. [PMID: 28012821 DOI: 10.1016/j.jdermsci.2016.12.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Revised: 11/24/2016] [Accepted: 12/05/2016] [Indexed: 11/19/2022]
Abstract
BACKGROUND A novel chemiluminescent enzyme immunoassay (CLEIA) was recently developed to quantify autoantibodies specific for desmogleins (Dsgs) and BP180, the target antigens of pemphigus and pemphigoid. This assay is automated and highly accurate and efficient. OBJECTIVE To validate the use of the CLEIA for detection of autoantibodies during the clinical courses of patients with pemphigus and pemphigoid. METHODS To define cut-off values for Dsg1, Dsg3, and BP180, we evaluated 47 serum samples from patients with pemphigus foliaceus (PF), 59 from those with pemphigus vulgaris (PV), 52 from those with bullous pemphigoid (BP), and 995 from healthy individuals. We also evaluated any fluctuations in CLEIA titers according to disease activity during the clinical course of 10 cases each of PF, PV, and BP. We used clinical symptom scores, the pemphigus disease area index (PDAI) and the bullous pemphigoid disease area index (BPDAI), to evaluate disease activity. RESULTS The cut-off values for the CLEIA titers determined by the Youden index were 15.4U/mL for Dsg1, 14.9U/mL for Dsg3, and 16.8U/mL for BP180. CLEIA titers fluctuated in parallel with the PDAI/BPDAI scores in 28 of the 30 cases with PF, PV, or BP. Although the CLEIA and enzyme-linked immunosorbent assay (ELISA) values in the same samples differed substantially in some cases, the concordance rates of positive/negative results between the CLEIA and ELISA were 96% for Dsg1, 97% for Dsg3, and 96% for BP180. CONCLUSION The CLEIA, a newly developed, highly effective autoantibody detection system, is as reliable as ELISA for evaluation of the clinical courses of pemphigus and pemphigoid.
Collapse
Affiliation(s)
- Yumi Fujio
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi Shinjuku, Tokyo, 160-8582, Japan.
| | - Kazuo Kojima
- Medical & Biological Laboratories Co., LTD, 4-5-3 Sakae, Naka-Ku, Nagoya, Aichi, 460-0008, Japan.
| | - Masahiro Hashiguchi
- Medical & Biological Laboratories Co., LTD, 4-5-3 Sakae, Naka-Ku, Nagoya, Aichi, 460-0008, Japan.
| | - Masatoshi Wakui
- Department of Laboratory Medicine, Keio University School of Medicine, 35 Shinanomachi Shinjuku, Tokyo, 160-8582, Japan.
| | - Mitsuru Murata
- Department of Laboratory Medicine, Keio University School of Medicine, 35 Shinanomachi Shinjuku, Tokyo, 160-8582, Japan.
| | - Masayuki Amagai
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi Shinjuku, Tokyo, 160-8582, Japan.
| | - Jun Yamagami
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi Shinjuku, Tokyo, 160-8582, Japan.
| |
Collapse
|
12
|
Zehnacker L, Nevers MC, Sinou V, Parzy D, Créminon C, Parzy D, Azoulay S. Development of sensitive direct chemiluminescent enzyme immunoassay for the determination of dihydroartemisinin in plasma. Anal Bioanal Chem 2015; 407:7823-30. [PMID: 26280205 DOI: 10.1007/s00216-015-8951-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Revised: 07/28/2015] [Accepted: 07/31/2015] [Indexed: 10/23/2022]
Abstract
Despite significant progress in prevention and therapy, malaria is still one of the world's leading major diseases due to its high morbidity and mortality. Recommended treatments by the World Health Organization include the use of artemisinin and artemisinin derivative-based combination therapies. To allow efficient patient monitoring during antimalarial therapy without the use of expensive apparatus, we developed a sensitive direct chemiluminescent enzyme immunoassay for the determination of dihydroartemisinin in biological fluids. To produce specific antibodies against dihydroartemisinin (DHA), a synthetic DHA derivative was coupled to bovine serum albumin as the immunogen. In parallel, a new, rapid, and efficient procedure to covalently link glycoprotein to all amine-containing molecules has been established and the enzyme tracer was prepared by chemically coupling the DHA derivative in combination with SBP rather than the more commonly used HRP. It allowed us to develop, after optimization of the luminescent reagent, a sensitive and stable luminescent EIA, with a LLOQ of 90 pg mL(-1). This assay compares favorably with the most efficient HPLC methods previously reported with a LLOQ close to 1 ng mL(-1) and shows good precision and efficiency since recovery from human plasma spiked with DHA ranged between 91 and 103%, with coefficients of variation of <13%. To date, no immunoassay for DHA has been applied to plasma analysis and this EIA should be very useful in all clinical laboratories for rapid and cost-effective analysis.
Collapse
Affiliation(s)
- Laura Zehnacker
- Institut de Chimie de Nice, UMR 7272 CNRS, Université Nice Sophia Antipolis, Parc Valrose, 06108, Nice, France
| | - Marie-Claire Nevers
- CEA, iBiTecS, Service de Pharmacologie et d'Immunoanalyse, 91191, Gif sur Yvette, France
| | - Véronique Sinou
- Faculté de Pharmacie, UMR-MD3, Aix-Marseille Université, 27, Boulevard Jean Moulin, 13385, Marseille, France
| | - Dominique Parzy
- K-Plan, 66 Boulevard Niels Bohr, 69100, Villeurbanne, France
| | - Christophe Créminon
- CEA, iBiTecS, Service de Pharmacologie et d'Immunoanalyse, 91191, Gif sur Yvette, France
| | - Daniel Parzy
- Faculté de Pharmacie, UMR-MD3, Aix-Marseille Université, 27, Boulevard Jean Moulin, 13385, Marseille, France
| | - Stéphane Azoulay
- Institut de Chimie de Nice, UMR 7272 CNRS, Université Nice Sophia Antipolis, Parc Valrose, 06108, Nice, France.
| |
Collapse
|
13
|
Nagai C, Minamino N. Direct chemiluminescent enzyme immunoassay for atrial natriuretic peptide in mammalian plasma using a PEGylated antibody. Anal Biochem 2014; 461:10-6. [PMID: 24907507 DOI: 10.1016/j.ab.2014.05.022] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2014] [Revised: 05/21/2014] [Accepted: 05/24/2014] [Indexed: 01/01/2023]
Abstract
Atrial natriuretic peptide (ANP) is a peptide hormone that is synthesized and secreted by cardiac tissues and plays a pivotal role in maintaining cardiovascular homeostasis. Clinically, ANP is used as a marker of cardiovascular diseases, including heart failure. Although multiple ANP assays are currently available, a more sensitive assay is required for the direct measurement of plasma ANP where there is limited plasma availability, especially in mouse experiments. In the current study, we developed a plate-based sandwich chemiluminescent enzyme immunoassay for the measurement of plasma ANP in rats and mice without the need for prior extraction. To minimize nonspecific binding, we performed a single-step PEGylation procedure targeting the immobilized antibody, which markedly improved the assay's sensitivity and linearity. The linear range was 0.1 to 250 pM, and the minimum detection limit was 0.13 pM, 5-fold lower than the lowest value of the commercially available kits. ANP was directly measured in plasma samples without detectable cross-reactivity with B- and C-type natriuretic peptides. The accuracy of the assay was confirmed by spike recovery tests and dilution tests and by comparison with a conventional radioimmunoassay. Based on the species cross-reactivity, this assay can be used to measure human ANP.
Collapse
Affiliation(s)
- Chiaki Nagai
- Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka 565-8565, Japan
| | - Naoto Minamino
- Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka 565-8565, Japan.
| |
Collapse
|